KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Land & Improvements: 2012-2024

Historic Land & Improvements for Teva Pharmaceutical Industries (TEVA) over the last 13 years, with Dec 2024 value amounting to $213.0 million.

  • Teva Pharmaceutical Industries' Land & Improvements fell 13.41% to $213.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was $213.0 million, marking a year-over-year decrease of 13.41%. This contributed to the annual value of $213.0 million for FY2024, which is 13.41% down from last year.
  • Per Teva Pharmaceutical Industries' latest filing, its Land & Improvements stood at $213.0 million for FY2024, which was down 13.41% from $246.0 million recorded in FY2023.
  • In the past 5 years, Teva Pharmaceutical Industries' Land & Improvements ranged from a high of $292.0 million in FY2020 and a low of $213.0 million during FY2024.
  • Its 3-year average for Land & Improvements is $235.0 million, with a median of $246.0 million in 2023.
  • Data for Teva Pharmaceutical Industries' Land & Improvements shows a maximum YoY dropped of 13.41% (in 2024) over the last 5 years.
  • Yearly analysis of 5 years shows Teva Pharmaceutical Industries' Land & Improvements stood at $292.0 million in 2020, then decreased by 10.27% to $262.0 million in 2021, then dropped by 6.11% to $246.0 million in 2022, then remained steady at $246.0 million in 2023, then dropped by 13.41% to $213.0 million in 2024.